ES2130509T3 - Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores. - Google Patents

Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores.

Info

Publication number
ES2130509T3
ES2130509T3 ES95120394T ES95120394T ES2130509T3 ES 2130509 T3 ES2130509 T3 ES 2130509T3 ES 95120394 T ES95120394 T ES 95120394T ES 95120394 T ES95120394 T ES 95120394T ES 2130509 T3 ES2130509 T3 ES 2130509T3
Authority
ES
Spain
Prior art keywords
carnitine
immunosuppressants
cyclosporine
derivatives
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95120394T
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2130509T3 publication Critical patent/ES2130509T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBE EL USO DE L-CARNITINA O DE UNA L-CARNITINA DE ALCANOILO O SUS SALES FARMACOLOGICAMTNE ACEPTABLES PARA PRODUCIR UN MEDICAMENTO PARA INHIBIR LA NEFROTOXICIDAD Y VASCULOTOXICIDAD RESULTANTE DE LA ADMINISTRACION DE UNA DROGA INMUNOSUPRESORA, TAL COMO LA CICLOSPORINA-A, TACROLIMUS, RAPAMICINA Y DEOXIESPERGUALINA.
ES95120394T 1995-01-20 1995-12-22 Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores. Expired - Lifetime ES2130509T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Publications (1)

Publication Number Publication Date
ES2130509T3 true ES2130509T3 (es) 1999-07-01

Family

ID=11402949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95120394T Expired - Lifetime ES2130509T3 (es) 1995-01-20 1995-12-22 Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores.

Country Status (13)

Country Link
US (2) US5955424A (es)
EP (1) EP0722724B1 (es)
JP (1) JPH08231390A (es)
KR (1) KR100443730B1 (es)
AT (1) ATE177946T1 (es)
CA (1) CA2167456A1 (es)
DE (1) DE69508551T2 (es)
DK (1) DK0722724T3 (es)
ES (1) ES2130509T3 (es)
GR (1) GR3030545T3 (es)
IT (1) IT1277147B1 (es)
TW (1) TW445145B (es)
ZA (1) ZA96431B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
IT1306179B1 (it) * 1999-07-28 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
MXPA03003230A (es) * 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
JPH01213258A (ja) * 1988-02-23 1989-08-28 Kyowa Hakko Kogyo Co Ltd カルニチンおよびカルニチンアミドの精製法

Also Published As

Publication number Publication date
JPH08231390A (ja) 1996-09-10
ATE177946T1 (de) 1999-04-15
DE69508551D1 (de) 1999-04-29
EP0722724B1 (en) 1999-03-24
TW445145B (en) 2001-07-11
KR960029314A (ko) 1996-08-17
GR3030545T3 (en) 1999-10-29
ITRM950037A0 (it) 1995-01-20
CA2167456A1 (en) 1996-07-21
IT1277147B1 (it) 1997-11-04
KR100443730B1 (ko) 2004-10-14
ITRM950037A1 (it) 1996-07-20
DE69508551T2 (de) 1999-09-02
EP0722724A1 (en) 1996-07-24
US5958941A (en) 1999-09-28
ZA96431B (en) 1996-08-08
DK0722724T3 (da) 1999-10-11
US5955424A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ES2130509T3 (es) Empleo de l-carnitina y sus derivados para reducir los efectos toxicos de ciclosporina-a y otros inmunosupresores.
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
ES2161290T3 (es) Derivados de quinazolina.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2137628T3 (es) Derivados de estilbeno y composiciones farmaceuticas que los contienen.
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
MX9207495A (es) Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
MX9300399A (es) Derivados heterotriciclicos.
DE69620761D1 (de) Pharmazeutisches praeparat auf der basis eines diclofenac-salzes und der verbindung thiocolchicosid
DK0840738T3 (da) Colchicinderivater, deres anvendelse og formuleringer indeholdende dem
AR005468A1 (es) Nuevos derivados de benzoilguanidina, procedimientos para su preparacion y su empleo en la preparacion de medicamentos.
ES2070478T3 (es) El empleo de acetil l-carnitina en el tratamiento terapeutico de coma.
ES2195538T3 (es) Composicion farmaceutica que comprende una combinacion de isomeros dextro y levo de sotalol.
AR004503A1 (es) Uso de l-carnitina, l-carnitinas acilicas en las cuales el gruo acilo, lineal o ramificado, tiene entre 2 y 6 atomos de carbono y sus salesfarmaceuticamente aceptables, y composiciones farmaceuticas que comprenden tales compuestos
ES2182090T3 (es) Nuevos derivados de pirrol.
ECSP003551A (es) Complejo farmaceutico
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
ES2181506T3 (es) Vancoresmicina, un procedimiento para su produccion y su uso como producto farmaceutico.
HN2000000057A (es) Derivados de i - trifluorometil-4-hidroxi-7-piperidinil- aminometilcromano.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 722724

Country of ref document: ES